EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Folliculin (FLCN) in Thyroid Tumors: Incidence, Significance, and Role as a Driver Gene and Secondary Alteration

Faisal A Hassan, Camryn Slone iD, Robert J McDonald, Julie C Dueber, Adeel M Ashraf, Melina J Windon, Oliver J Fackelmayer, Cortney Y Lee, Therese J Bocklage iD, Derek B Allison iD

Current Oncology · 2025

DOI: 10.3390/curroncol32040224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Faisal A Hassan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40506, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Thyroid Neoplasms, Tumor Suppressor Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Pathology & Laboratory Medicine at the University of Kentucky College of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid carcinomas are driven by diverse molecular alterations, but the tumor suppressor gene folliculin (FLCN), best known for its role in Birt–Hogg–Dubé (BHD) syndrome, has received limited attention in thyroid tumors. Here, we describe two thyroid tumors with pathogenic FLCN alterations—one germline and one somatic—and analyze the broader prevalence and significance of FLCN in thyroid carcinomas using multiple large sequencing datasets, including ORIEN-AVATAR. Patient 1, with a germline FLCN mutation and a history of BHD syndrome, presented with a well-circumscribed oncocytic adenoma. Molecular testing confirmed biallelic FLCN inactivation, but no additional mutations or aggressive features were observed, and the patient remained disease-free post-thyroidectomy. Patient 2 harbored a somatic FLCN mutation in an oncocytic poorly differentiated thyroid carcinoma, which exhibited extensive angioinvasion, high proliferative activity, and concurrent TP53 and RB1 mutations. The tumor progressed with metastatic disease despite multimodal treatment. Thyroid carcinomas revealed FLCN alterations in 1.1% of cases. Pathogenic mutations were rare but associated with oncocytic morphology, while homozygous deletions occurred more frequently in genomically unstable tumors, including anaplastic thyroid carcinoma. These findings suggest FLCN mutations may act as early oncogenic drivers in oncocytic thyroid neoplasms, while deletions represent secondary events in aggressive tumor evolution. The lack of FLCN coverage in standard thyroid molecular panels likely underestimates its clinical relevance. Including FLCN in genetic testing could improve tumor detection and characterization, particularly in BHD patients who may benefit from routine thyroid screening. Further studies are needed to clarify FLCN’s role in thyroid cancer pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene ProteinsThyroid NeoplasmsTumor Suppressor ProteinsHumansBirt-Hogg-Dube SyndromeIncidenceMutation

Stichwörter der Autor:innen

Brit–Hogg–Dubefolliculinmolecular testingpreoperative molecular testingthyroid cancer

Substanzen

FLCN protein, humanProto-Oncogene ProteinsTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Pathology & Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40506, USA.
  • Kentucky College of Medicine, University of Kentucky, Lexington, KY 40506, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Kentucky College of Medicine, Lexington, KY 40506, USA.
  • Department of Surgery, Division of Endocrine Surgery, University of Kentucky College of Medicine, Lexington, KY 40506, USA.
  • Markey Cancer Center, Lexington, KY 40536, USA.

ORCID-Profile: Camryn Slone, Therese J Bocklage, Derek B Allison

Förderung

  • NCI NIH HHS
  • Department of Pathology & Laboratory Medicine at the University of Kentucky College of Medicine

Zitieren

APA

Hassan, F. A., Slone, C., McDonald, R. J., Dueber, J. C., Ashraf, A. M., Windon, M. J., Fackelmayer, O. J., Lee, C. Y., Bocklage, T. J., & Allison, D. B. (2025). Folliculin (FLCN) in Thyroid Tumors: Incidence, Significance, and Role as a Driver Gene and Secondary Alteration. Current Oncology. https://doi.org/10.3390/curroncol32040224

Vancouver

Hassan FA, Slone C, McDonald RJ, Dueber JC, Ashraf AM, Windon MJ, et al. Folliculin (FLCN) in Thyroid Tumors: Incidence, Significance, and Role as a Driver Gene and Secondary Alteration. Current Oncology. 2025. doi:10.3390/curroncol32040224

BibTeX
@article{Hassan2025,
  author = {Hassan, Faisal A and Slone, Camryn and McDonald, Robert J and Dueber, Julie C and Ashraf, Adeel M and Windon, Melina J and Fackelmayer, Oliver J and Lee, Cortney Y and Bocklage, Therese J and Allison, Derek B},
  title = {Folliculin (FLCN) in Thyroid Tumors: Incidence, Significance, and Role as a Driver Gene and Secondary Alteration},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32040224}
}
Kostenlos starten →